Abstract
Background: Drug-induced liver injury (DILI) is a major clinical problem and its pathogenesis is poorly understood. The association of DILI with polymorphisms in hepatobiliary transport systems suggests a role for transport proteins in the pathogenesis of DILI. Aim: To investigate expression and tissue distribution of hepatobiliary transport systems in DILI. Methods: Expression of the canalicular bile salt export pump BSEP (ABCC11), phospholipid flippase MDR3 (ABCB4) and bilirubin export pump MRP2 (ABCC2) was assessed immunohistochemically in liver biopsies from 23 patients with DILI. Results: Of 12 patients with cholestatic DILI (mostly due to antibiotics), 8 displayed a marked reduction of MRP2, MDR3 and BSEP expression. Transporter staining was normal in 4 patients with cholestatic DILI. In 11 patients with necroinflammatory hepatocellular injury (most frequently caused by NSAIDs), transporter staining was normal in areas where hepatocyte morphology was preserved. Due to hepatocyte necrosis and the reduction of the hepatocyte number, overall transporter expression was reduced without a reduction in transporter expression at the single hepatocyte level. Conclusions: Canalicular ABC transporter expression is profoundly disturbed in most cases of cholestatic DILI. Drug-induced hepatitis does not lead to repression of transporter expression but to hepatocyte drop-outs with a numerical loss of bile canaliculi.
Journal Section:
Original Paper
References
1.
Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, et al: Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-455.
[PubMed]
2.
Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K: Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005;61:135-143.
[PubMed]
3.
Navarro VJ, Senior JR: Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739.
[PubMed]
4.
Trauner M, Meier PJ, Boyer JL: Molecular pathogenesis of cholestasis. N Engl J Med 1998;339:1217-1227.
[PubMed]
5.
Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-277.
[PubMed]
6.
Bohan A, Boyer JL: Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis 2002;22:123-136.
[PubMed]
7.
Pauli-Magnus C, Meier PJ: Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006;44:778-787.
[PubMed]
8.
Kojima H, Sakurai S, Uemura M, Kitamura K, Kanno H, Nakai Y, Fukui H: Disturbed colocalization of multidrug resistance protein 2 and radixin in human cholestatic liver diseases. J Gastroenterol Hepatol 2008;23:e120-e128.
[PubMed]
9.
Van Staden CJ, Morgan RE, Ramachandran B, Chen Y, Lee PH, Hamadeh HK: Membrane vesicle ABC transporter assays for drug safety assessment. Curr Protoc Toxicol 2012; Chapter 23: Unit 23.5.
[PubMed]
10.
Trauner M, Fickert P, Wagner M: MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007;27:77-98.
[PubMed]
11.
Trauner M, Fickert P, Halilbasic E, Moustafa T: Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 2008;158:542-548.
[PubMed]
12.
Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, et al: Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007;17:47-60.
[PubMed]
13.
Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, Chon CY, et al: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 2007;17:403-415.
[PubMed]
14.
Danan G, Benichou C: Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
[PubMed]
15.
Benichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-276.
[PubMed]
16.
Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H: Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008;48:821-828.
[PubMed]
17.
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, et al: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952.
[PubMed]
18.
Lenzen R, Stremmel W, Strohmeyer G: Antiarrhythmic drugs impair hepatic uptake and secretory function by different mechanisms in the isolated perfused rat liver. Biochim Biophys Acta 1991;1074:406-412.
[PubMed]
19.
Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis trough inhibition of the paepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000;118:422-430.
[PubMed]
20.
Kubitz R, Wettstein M, Warskulat U, Haussinger D: Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 1999;116:401-410.
[PubMed]
21.
Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, et al: The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997;113:255-264.
[PubMed]
22.
Green RM, Hoda F, Ward KL: Molecular cloning and characterization of the murine bile salt export pump. Gene 2000;241:117-123.
[PubMed]
23.
Zollner G, Trauner M: Mechanisms of cholestasis. Clin Liver Dis 2008;12:1-26.
[PubMed]
24.
Zollner G, Marschall HU, Wagner M, Trauner M: Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006;3:231-251.
[PubMed]
25.
Zollner G, Trauner M: Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009;156:7-27.
[PubMed]
26.
Popper H, Schaffner F: Pathophysiology of cholestasis. Hum Pathol 1970;1:1-24.
[PubMed]
27.
Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, et al: Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003;38:717-727.
[PubMed]
28.
Trauner M, Boyer JL: Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003;83:633-671.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
